Viatris Inc.

Company Snapshot

Founded: 2020
Entity Type: Public
Employees: 32,000
Region: North America and Europe
Revenue: $14,692.8 Millions
Revenue Year: 2024
Headquarter: Pennsylvania, U.S.
Key Geographics: North America, Europe, Asia-Pacific, Rest of the World

Company Overview

Viatris Inc., headquartered in Pittsburgh, Pennsylvania, is a global pharmaceutical company formed in November 2020 by merging Mylan N.V. and Pfizer Inc.’s Upjohn division. The company focuses on providing access to affordable, high-quality medicines worldwide, operating in numerous countries with a diverse portfolio of generic drugs and biosimilars. Viatris Inc. is committed to improving global healthcare access and empowering individuals to lead healthier lives.

The executive team leads the company’s efforts, and it invests in R&D to advance its product pipeline. Viatris Inc. engages in various corporate social responsibility initiatives as a pharmaceutical entity, including sustainability and community engagement. Not all the products listed have been approved for use in all countries.

Viatris Inc. In Reports

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

BCC Research expert says the Therapies for Rheumatoid Arthritis market report analyzes the market trends of therapies for rheumatoid arthritis with data from 2024, estimates from 2025, projections of CAGR through 2030. ...

Global Markets for Allergy Diagnostics and Treatments

BCC Research Market Analyst says global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030.

Needle-Free Devices: Technologies and Global Markets

BCC Research Market Analyst says global market for needle-free devices was valued at $15.5 billion in 2024 and is estimated to increase from $17.0 billion in 2025 to reach $27.7 billion by 2030.

Company's Business Segments

  • Brands : Lipitor, Norvasc, Caduet, Inspra, Nitrostat, Revatio, Dilatin, Lyrica, Neurontin, Relpax
  • Generics : Wixela, Inhub, ADVAIR DISKUS, Glatiramer acetate injection, Copaxone

Applications/End User Industries

  • Governments
  • Healthcare Providers
  • Consumer
  • Pharmaceuticals
AI: Your Say